News Releases

NEWS RELEASES

  • Webcast
    X Zogenix at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
    10/02/18 10:30 AM EDT
    Click here for webcast

    Zogenix at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
    10/02/18 10:30 AM EDT
Date Title and Summary  
Toggle Summary Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to three new non-executive employees.
Toggle Summary Zogenix to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
EMERYVILLE, Calif. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, and Michael P.
Toggle Summary Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to four new non-executive employees.
Toggle Summary Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome
67% of Patients Achieved At Least a 50% Reduction in Convulsive Seizures Global Phase 3 Randomized, Controlled Study in LGS Currently Enrolling Patients EMERYVILLE, Calif. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the
Toggle Summary Zogenix Announces New Data on Psychological and Socioeconomic Impact of Dravet Syndrome and Other Epileptic Encephalopathies at 13th European Congress on Epileptology
EMERYVILLE, Calif. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced new findings from multiple studies assessing the psychological and socioeconomic
Toggle Summary Zogenix Prices Public Offering of Common Stock
EMERYVILLE, Calif. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it has priced an underwritten public offering of 6,000,000 shares of its
Toggle Summary Zogenix Announces Proposed Public Offering of 6,000,000 Shares of Common Stock
EMERYVILLE, Calif. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it intends to offer and sell, subject to market and other conditions,
Toggle Summary Zogenix Provides Corporate Update and Reports Second Quarter Financial Results
Reported positive top-line results from second pivotal Phase 3 trial of ZX008 in patients with Dravet syndrome, Study 1504 Submission of U.S. and EU regulatory filings for ZX008 in Dravet syndrome anticipated by year-end 2018 Actively enrolling global Phase 3 trial of ZX008 for treatment of
Toggle Summary Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to five new non-executive employees.  The awards
Toggle Summary Zogenix to Release Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 6
EMERYVILLE, Calif. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30, 2018 ,
Toggle Summary Zogenix Announces Positive Top-line Results from Second Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008 versus Placebo for Adjunctive Treatment of Seizures ZX008 Also Demonstrated Statistical Significance in All Key Secondary Endpoints U.S. and EU Regulatory Submissions on Track for Fourth Quarter of 2018
Toggle Summary Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif. , July 02, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued an inducement award to Ashish Sagrolikar, the company’s newly
Toggle Summary Zogenix Welcomes New Global Chief Commercial Officer
Ashish Sagrolikar Brings Over 25 Years of Global Pharmaceutical  Sales, Marketing and Operations Experience to Zogenix EMERYVILLE, Calif. , July 02, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system
Toggle Summary Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif. , June 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to four new non-executive employees.  The awards
Toggle Summary Zogenix to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference
EMERYVILLE, Calif. , May 14, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, and Michael P.
Toggle Summary Zogenix Provides Corporate Update and Reports First Quarter Financial Results
Following receipt of Breakthrough Therapy Designation, conducted successful Type B meeting with FDA confirming adequacy of Phase 3 program for ZX008 NDA in Dravet syndrome Study 1504 fully enrolled with 87 randomized patients; top-line results expected late June/early July On-track to submit U.S.
Toggle Summary Zogenix to Release First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9
EMERYVILLE, Calif. , May 04, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2018 ,
Toggle Summary Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif. , May 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to six new non-executive employees.  The awards
Toggle Summary Zogenix Announces Initial Quality of Life and Cognitive Function Data From Phase 3 Trial of ZX008 in Dravet Syndrome
ZX008 Patients Experienced Significant Improvements on Select Measures of Quality of Life and Executive Function Compared to Those on Placebo Data Presented During Emerging Therapies Plenary Session at 2018 American Academy of Neurology Annual Meeting EMERYVILLE, Calif.
Toggle Summary Zogenix Announces Presentation of New Efficacy and Safety Data from its First Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Efficacy and Safety Data in Patients on ZX008 Who Previously Failed Stiripentol Treatment Prior to Entry into First Phase 3 Trial (Study 1) Comparable to Results from Full Study 1 Population Patients on ZX008 Also Achieved Significant, Clinically Meaningful Reduction in Total Seizure Frequency
Toggle Summary Zogenix to Participate in LEERINK Partners CNS Day
EMERYVILLE, Calif. , April 11, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, Gail Farfel , Ph.D., Executive Vice
Toggle Summary Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
ZX008 Granted Breakthrough Therapy Designation in Dravet syndrome by FDA Last patient randomized into second Phase 3 clinical trial of ZX008 in patients with Dravet syndrome, Study 1504 Initiated global Phase 3 clinical trial for ZX008 in Lennox-Gastaut syndrome EMERYVILLE, Calif.
Toggle Summary Zogenix to Release Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call and Webcast on March 6
EMERYVILLE, Calif. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended
Toggle Summary Zogenix to Participate in Leerink Partners 7th Annual Global Healthcare Conference
EMERYVILLE, Calif. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, and Michael P.
Toggle Summary Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet Syndrome
Designation Based on Positive Results from Study 1, the First Pivotal Phase 3 Trial of ZX008 EMERYVILLE, Calif. , Feb. 06, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today
Toggle Summary Zogenix Completes Enrollment in Second ZX008 Phase 3 Clinical Trial in Dravet Syndrome
Study 1504 Top-Line Data on Track for 2Q 2018 EMERYVILLE, Calif. , Jan. 31, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that the last patient has been randomized
Toggle Summary Zogenix Announces New Positive Efficacy and Safety Data from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
ZX008 Patients More Likely to Achieve Clinically Meaningful Reduction in Seizure Frequency Compared to Those on Placebo Parents/Caregivers and Investigators Rated Patients Treated with ZX008 as Very Much Improved or Much Improved in Overall Condition Compared to Placebo Company to Host Call with
Toggle Summary Zogenix Announces Initiation of Phase 3 Trial for ZX008 in Lennox-Gastaut Syndrome
EMERYVILLE, Calif. , Nov. 29, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that the first child has enrolled in the Phase 3 clinical trial for the Company’s lead
Toggle Summary Zogenix to Participate in the Global Mizuho Investor Conference 2017
EMERYVILLE, Calif. , Nov. 29, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, and Michael P.
Toggle Summary Zogenix To Host Call with Pediatric Epilepsy Expert Joseph Sullivan, M.D., on Dravet Syndrome and ZX008 on Monday, December 4
EMERYVILLE, Calif. , Nov. 28, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will host an update call on Dravet syndrome and the Company’s investigational
Toggle Summary New Data from Zogenix’s Phase 3 Trial of ZX008 in Dravet Syndrome (Study 1) and Findings on Disease Impact to be Presented at 71st American Epilepsy Society Annual Meeting
Updated Results of Phase 2 Study of ZX008 in Lennox Gastaut Syndrome to be Presented Data Demonstrating Disease Burden and Negative Impact on Quality of Life of Patients and Families Will Also be Presented EMERYVILLE, Calif. , Nov. 21, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc.
Toggle Summary Zogenix to Present at Stifel 2017 Healthcare Conference
EMERYVILLE, Calif. , Nov. 14, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO of Zogenix , will present a corporate
Toggle Summary Zogenix Provides Corporate Update and Reports Third Quarter 2017 Financial Results
During the third quarter, the Company announced positive top-line results from its Phase 3 Study 1 of ZX008 in patients with Dravet syndrome Study 1 met primary endpoint of reduction in frequency of convulsive seizures (p
Toggle Summary Zogenix to Release Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7
EMERYVILLE, Calif. , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter ended September 30,
Toggle Summary High Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds
(GLOBE NEWSWIRE via COMTEX) --Global survey of 584 caregivers of children, young adults and adults with Dravet illustrates the detrimental effect of debilitating, frequent seizures on quality of life and co-morbidities Results suggest a need for more effective antiepileptic treatments EMERYVILLE,
Toggle Summary Interim Survey Results Demonstrate Impact on Siblings of Children Suffering from Severe Epilepsy
Findings Presented by Zogenix at the NORD Rare Diseases and Orphan Products Breakthrough Summit in Washington, D.C. EMERYVILLE, Calif. , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system
Toggle Summary Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
EMERYVILLE, Calif. , Oct. 05, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today the closing of its previously announced underwritten public offering of 7,705,000
Toggle Summary Zogenix Prices Public Offering of Common Stock
EMERYVILLE, Calif. , Oct. 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it has priced an underwritten public offering of 6,700,000 shares of its
Toggle Summary Zogenix Announces Proposed Public Offering of 4,300,000 Shares of Common Stock
EMERYVILLE, Calif. , Oct. 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it intends to offer and sell, subject to market and other conditions,
Toggle Summary Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008 versus Placebo for Adjunctive Treatment of Seizures ZX008 Also Demonstrated Statistical Significance in All Key Secondary Endpoints Zogenix to Host Conference Call Today at 8:30 AM Eastern Time / 5:30 AM
Toggle Summary Zogenix Provides Corporate Update and Reports Second Quarter 2017 Financial Results
Top-Line Results of First Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Expected in Third Quarter 2017 Second Phase 3 Clinical Trial in Dravet Syndrome, Study 1504, Enrolling According to Plan Orphan Drug Designation Granted by FDA for ZX008 in Lennox Gastaut Syndrome; Phase 3 Clinical Trial
Toggle Summary Zogenix to Release Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8
EMERYVILLE, Calif. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30,
Toggle Summary Zogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome
EMERYVILLE, Calif. , June 22, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced the U.S. Food & Drug Administration ( FDA ) has granted its investigational
Toggle Summary Zogenix to Present at the Jefferies 2017 Global Healthcare Conference
EMERYVILLE, Calif. , May 31, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith , Executive Vice President, Chief Financial Officer &
Toggle Summary Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry
New Research Expands Understanding of ZX008 Mechanism in Treating Seizures EMERYVILLE, Calif. , May 22, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that
Toggle Summary Zogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results
Completed Enrollment of Study 1, First Phase 3 Clinical Trial of ZX008 in Dravet Syndrome;  Top-Line Results Expected in Third Quarter 2017 IND Accepted by FDA for Phase 3 Clinical Trial of ZX008 in Lennox Gastaut Syndrome Company will host a conference call today at 4:30 p.m. EDT / 1:30 p.m.
Toggle Summary Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome
Study 1 Top-Line Data on Track for 3Q 2017 EMERYVILLE, Calif. , April 27, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that the last patient has been
Toggle Summary Zogenix to Release First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 4
EMERYVILLE, Calif. , April 27, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31,
Toggle Summary Zogenix to Participate in the Oppenheimer 27th Annual Healthcare Conference
EMERYVILLE, Calif. , March 15, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith , Executive Vice President, Chief Financial Officer &
Toggle Summary Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
Top-Line Data for First Phase 3 Study Expected in 3Q 2017 ZX008 Phase 3 Pivotal Study 1504 Initiated – Target Data Readout by End of 2017 Planned Initiation of Phase 3 study of ZX008 in Lennox Gastaut Syndrome in 2H 2017 Company will host a conference call today at 4:30 p.m. EST / 1:30 p.m.
Toggle Summary Zogenix to Release Fourth Quarter and Full-Year 2016 Financial Results and Host Conference Call and Webcast on March 9
EMERYVILLE, Calif. , March 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year
Toggle Summary Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome
EMERYVILLE, Calif. , March 01, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that the European Commission (EC) has designated ZX008 (fenfluramine) as an
Toggle Summary Zogenix to Participate in the 2017 RBC Capital Markets Healthcare Conference
EMERYVILLE, Calif. , Feb. 15, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith , Executive Vice President, Chief Financial Officer &
Toggle Summary Zogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome
Study 1504 Part of Phase 3 Program for ZX008 in Dravet Syndrome Safety and Efficacy Portion of Study Expanded from EU to Include Sites in U.S. and Canada EMERYVILLE, Calif. , Feb. 13, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the
Toggle Summary Zogenix to Participate in the Leerink Partners 6th Annual Global Healthcare Conference
EMERYVILLE, Calif. , Feb. 08, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, will present a corporate update
Toggle Summary Zogenix Announces Issuance of U.S. Patent for ZX008 in Dravet Syndrome
Issued Patent is First Covering Company’s Treatment of Seizures Associated with Dravet Syndrome Using Fenfluramine as an Adjunctive Therapy EMERYVILLE, Calif. , Jan. 30, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan
Toggle Summary Zogenix Announces CFO Transition
Ann D. Rhoads to Depart Company Following Transition Period; Biopharmaceutical Industry Veteran Michael P. Smith Appointed New CFO EMERYVILLE, Calif. , Jan. 05, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and
Toggle Summary Zogenix Announces New Efficacy and Safety Data for ZX008 in Treatment of Seizures in Lennox Gastaut Syndrome & Dravet Syndrome
New Clinical Data Presented at 70 th Annual American Epilepsy Society Meeting Posters Highlighting Potential Protective Effect of ZX008 in Pre-Clinical Model of Sudden Unexpected Death in Epilepsy (SUDEP) and Results of Roundtable Discussions Evaluating Burden of Illness on Caregivers in Dravet
Toggle Summary New Data on Zogenix’s ZX008 for Lennox Gastaut Syndrome & Dravet Syndrome to be Presented at 70th Annual American Epilepsy Society Meeting
Interim Results of Investigator Initiated Phase 2 study of ZX008 in Lennox Gastaut Syndrome to be Presented Update from Ongoing Open-Label Prospective Study of ZX008 in Dravet Syndrome Will Also be Presented EMERYVILLE, Calif. , Nov. 22, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc.
Toggle Summary Zogenix to Participate in Oppenheimer Life Sciences Summit 2016
EMERYVILLE, Calif. , Nov. 22, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Gail Farfel , Ph.D., Chief Development Officer, will participate in the
Toggle Summary Zogenix to Participate in Stifel 2016 Healthcare Conference
EMERYVILLE, Calif. , Nov. 08, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, will participate in a fireside
Toggle Summary Zogenix Provides Corporate Update and Reports Third Quarter 2016 Financial Results
Company will host a conference call today at 4:30 p.m. EST/1:30 p.m. PST EMERYVILLE, Calif. , Nov. 07, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today provided a
Toggle Summary Zogenix to Release Third Quarter 2016 Financial Results and Host Conference Call and Webcast on November 7
EMERYVILLE, Calif. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter ended September
Toggle Summary Zogenix to Participate in Two Upcoming Investor Conferences
EMERYVILLE, Calif. , Sept. 20, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, will present a corporate update
Toggle Summary Zogenix to have Significant Presence at 12th European Congress on Epileptology
Company’s Four Poster Presentations to Focus on ZX008 Open-Label Cohort and Burden of Dravet Syndrome EMERYVILLE, Calif. , Sept. 08, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)
Toggle Summary Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results
Company will host a conference call today at 4:30 p.m. EDT/1:30 p.m. PDT EMERYVILLE, Calif. , Aug. 09, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today provided a
Toggle Summary Zogenix to Release Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 9
EMERYVILLE, Calif. , Aug. 02, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30,
Toggle Summary Zogenix Announces Agreement to Refinance Debt, Further Increasing Company’s Expected 2017 Cash Balance
- Interest-only repayment provision results in $10 million increase to Zogenix’s expected cash balance at the end of 2017 - EMERYVILLE, Calif. , June 21, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system
Toggle Summary Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome
EMERYVILLE, Calif. , June 07, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of the second Phase 3 clinical trial, a multi-national study (Study 1502),
Toggle Summary Zogenix to Participate in Jefferies 2016 Healthcare Conference
EMERYVILLE, Calif. , May 31, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, will present a corporate update at the
Toggle Summary Zogenix Provides Corporate Update and Reports First Quarter 2016 Financial Results
Company will host a conference call today at 4:30 p.m. EDT/1:30 p.m. PDT EMERYVILLE, Calif. , May 10, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today provided a corporate update
Toggle Summary Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome
Patient and Caregiver Sleep Quality and Quality of Life Data Reported for First Time New Clinical Data Presented at 14 th International Child Neurology Congress on the Use of Low-Dose Fenfluramine in Managing Seizures Associated With Dravet Syndrome EMERYVILLE, Calif.
Toggle Summary Zogenix to Release First Quarter 2016 Financial Results and Host Conference Call and Webcast on May 10
EMERYVILLE, Calif. , May 03, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2016 after
Toggle Summary New Data on Zogenix's ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress
Podium Presentation to Highlight Efficacy, Cardiovascular Safety, Sleep Quality, and Quality of Life in Patients Receiving Low-Dose Fenfluramine for the Treatment of Dravet Syndrome EMERYVILLE, Calif. , April 21, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc.
Toggle Summary Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2015 Financial Results
Company will host a conference call today at 4:30 p.m. EST/1:30 p.m. PST EMERYVILLE, Calif. , March 10, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today provided a corporate update
Toggle Summary Zogenix to Release Fourth Quarter and Full-Year 2015 Financial Results and Host Conference Call and Webcast on March 10
EMERYVILLE, Calif. , March 04, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended
Toggle Summary Zogenix to Participate in LEERINK Partners 5th Annual Global Healthcare Conference
EMERYVILLE, Calif. , Feb. 03, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, and Bradley S.
Toggle Summary Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome
EMERYVILLE, Calif. , Jan. 19, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced receipt of Fast Track designation from the U.S.
Toggle Summary Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome
SAN DIEGO , Jan. 11, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of the first Phase 3 clinical trial for the Company’s lead product candidate, ZX008,
Toggle Summary Zogenix Announces FDA Acceptance of Investigational New Drug Application for ZX008 Phase 3 Clinical Trial in Dravet Syndrome
SAN DIEGO, Dec. 14, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s investigational new drug
Toggle Summary Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome
New Clinical Data Presented at 69th Annual American Epilepsy Society Meeting on the Use of Low-Dose Fenfluramine in Managing Seizures Associated With Dravet Syndrome SAN DIEGO , Dec. 7, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the
Toggle Summary New Data on Zogenix's ZX008 for Dravet Syndrome to be Presented at 69th Annual American Epilepsy Society Meeting
Three Poster Presentations will Highlight Efficacy, Cardiovascular Safety and Mechanism of Action of Low-Dose Fenfluramine in the Treatment of Dravet Syndrome Zogenix will also Host a Scientific Exhibit Room : "History of the Use of Low-dose Fenfluramine in Pediatric Epilepsy" SAN DIEGO , Nov.
Toggle Summary Zogenix to Participate in Stifel 2015 Healthcare Conference
SAN DIEGO , Nov. 11, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, will present a corporate update at the Stifel 2015
Toggle Summary Zogenix Provides Corporate Update and Reports Third Quarter 2015 Financial Results
Company Will Host a Conference Call Today at 4:30 p.m. EST/1:30 p.m. PST SAN DIEGO , Nov. 9, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, provided a corporate update, and announced
Toggle Summary Zogenix to Release Third Quarter 2015 Financial Results and Host Conference Call & Webcast on November 9
SAN DIEGO , Nov. 2, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter ended September 30, 2015 after the
Toggle Summary Zogenix Provides Regulatory Update for ZX008
Company Continues to Expect Phase 3 Clinical Program to Begin in Fourth Quarter of 2015 SAN DIEGO , Oct. 19, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the recent
Toggle Summary Zogenix Reports Positive Top-Line Results From Relday(TM) Phase 1b Multi-Dose Clinical Trial
Product Candidate Now Phase 3 Ready Company Initiates Efforts to Secure Global Development and Commercialization Partner SAN DIEGO , Sept. 30, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS)
Toggle Summary Zogenix to Participate in the Leerink Partners 4th Annual Rare Disease Roundtable
SAN DIEGO , Sept. 23, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, will present a corporate update at the Leerink
Toggle Summary Zogenix to Participate in the Wells Fargo 2015 Healthcare Conference
SAN DIEGO , Sept. 3, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, will present a corporate update at the Wells Fargo
Toggle Summary Zogenix Provides Corporate Update and Reports Second Quarter 2015 Financial Results
Company Will Host a Conference Call Today at 4:30 p.m. EDT/1:30 p.m. PDT SAN DIEGO , Aug. 10, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, provided a corporate
Toggle Summary Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO , Aug. 5, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, announced today the closing of its previously announced underwritten public offering of
Toggle Summary Zogenix to Release Second Quarter 2015 Financial Results and Host Conference Call & Webcast on August 10
SAN DIEGO , Aug. 3, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30,
Toggle Summary Zogenix Prices Public Offering of Common Stock
SAN DIEGO , July 30, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, announced today that it has priced an underwritten public offering of 4,750,000 shares of
Toggle Summary Zogenix Announces Proposed Public Offering of 3,800,000 Shares of Common Stock
SAN DIEGO , July 28, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, announced today that it intends to offer and sell 3,800,000 shares of its common stock in
Toggle Summary Zogenix to Host Key Opinion Leader Meeting Tuesday, July 14, in New York City
SAN DIEGO , July 7, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, today announced that it will host a Key Opinion Leader breakfast focused on Dravet
Toggle Summary Zogenix Expands Senior Leadership Team to Further Drive Strategic Focus on CNS Disorders and Orphan Drug Development
Company Appoints Dr. Gail Farfel as Chief Development Officer and Dr. Thierry Darcis as General Manager, Europe SAN DIEGO , July 6, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system
Toggle Summary Zogenix to Participate in Cantor Fitzgerald Healthcare Conference
SAN DIEGO , July 6, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, will present a corporate
Toggle Summary Zogenix Announces Shareholders and Board of Directors Approve Reverse Stock Split
SAN DIEGO , June 18, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that at the annual general meeting of shareholders held earlier today,
Toggle Summary Zogenix Announces New Efficacy Data From a Long-Term Study of Low-Dose Fenfluramine for Treatment of Dravet Syndrome
New data presented at European Paediatric Neurology Society Congress in Vienna, Austria includes 10 patients who continued treatment with low-dose fenfluramine for Dravet syndrome following the original study published in 2012, plus 2 new patients who began treatment in 2011 During 5-year follow-up
Toggle Summary Zogenix Provides Corporate Update and Reports First Quarter 2015 Financial Results
Company Will Host a Conference Call Today at 4:30 p.m. EDT/1:30 p.m. PDT SAN DIEGO , May 11, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, provided a corporate
Toggle Summary Zogenix to Release First Quarter 2015 Financial Results and Host Conference Call & Webcast on May 11
SAN DIEGO , May 4, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2015
Toggle Summary Dr. Stephen Farr Appointed as CEO of Zogenix to Lead New Strategic Focus and Advance Late-Stage CNS Product Pipeline
SAN DIEGO , April 27, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that it is implementing its succession plan as the Company focuses on advancing
Toggle Summary Zogenix Closes Sale of Zohydro(R) ER Business to Pernix
Strategic Focus Shifts to Zogenix's High Value Late-Stage CNS Pipeline SAN DIEGO , April 24, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that it
Toggle Summary Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study
Results Anticipated in Third Quarter 2015, Positioning Zogenix for Potential World-Wide Partnering Opportunities for Relday SAN DIEGO , March 26, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central
Toggle Summary Zogenix Reports Fourth Quarter and Full Year 2014 Financial Results
Conference Call and Webcast to Discuss Fourth Quarter Results and Definitive Agreement to Sell Zohydro ER to Pernix; Scheduled for Today, March 10, at 4:30 p.m. ET Clinical and Regulatory Update Received FDA approval for new formulation of Zohydro ® ER (hydrocodone bitartrate) Extended-Release
Toggle Summary Zogenix Announces Agreement of Sale of Zohydro(R) ER Business to Pernix for $100 Million at Closing Plus Potential Milestones of $283.5 Million
Enables planned implementation of new strategic focus to developing a late-stage, high-value CNS pipeline Conference Call and Webcast on Tuesday, March 10 , at 4:30 p.m. ET Agreement Terms: $100 million in upfront consideration comprised of $30 million in cash, $20 million in Pernix common stock
Toggle Summary Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2014 Financial Results
Conference Call Scheduled for March 10, 2015 at 4:30 pm ET SAN DIEGO , March 2, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced it will release
Toggle Summary Zogenix Appoints Industry Veteran Renee Tannenbaum to Its Board of Directors
SAN DIEGO , Feb. 10, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that Renee Tannenbaum , Pharm.D., has been appointed as a new member of the
Toggle Summary Zogenix to Participate in Leerink Global Healthcare Conference
SAN DIEGO , Feb. 5, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that Ann Rhoads , Chief Financial Officer, will present at the Leerink Global
Toggle Summary Zogenix Receives FDA Approval of New Formulation of Zohydro(R) ER
Zohydro ER With BeadTek(TM) to be Available in the Second Quarter of 2015 SAN DIEGO , Jan. 30, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that the
Toggle Summary Zogenix Provides Business Update
SAN DIEGO , Jan. 12, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system (CNS) disorders, announced today a business update including recent company highlights,
Toggle Summary Zogenix to Participate in Oppenheimer 25th Annual Healthcare Conference
SAN DIEGO , Dec. 3, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Stephen Farr , President, and Ann Rhoads , Chief
Toggle Summary Results of Long-Term, Open-Label Study Published in the Journal of Pain Research Demonstrate the Safety, Tolerability and Effectiveness of Zohydro(R) ER
Findings Contribute to Growing Body of Evidence Supporting Efficacy and Safety Profile SAN DIEGO , Dec. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS)
Toggle Summary Zogenix to Participate in Stifel 2014 Healthcare Conference
SAN DIEGO , Nov. 12, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Zogenix management will present at the Stifel 2014
Toggle Summary Zogenix Reports Third Quarter 2014 Financial Results
Conference Call and Webcast Today, November 6 , at 4:30 p.m. ET Recent Business Highlights Submitted a supplemental New Drug Application (sNDA) for a modified formulation with potential abuse deterrent properties of Zohydro ® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, on September
Toggle Summary Zogenix and Purdue Pharma Exchange Waivers of Regulatory Exclusivity for Extended-Release Hydrocodone Products
SAN DIEGO , Oct. 31, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it has entered into an agreement with Purdue Pharma L.P.
Toggle Summary Zogenix Announces Conference Call and Webcast to Present Third Quarter 2014 Financial Results
Conference Call Scheduled for November 6, 2014 at 4:30 pm ET SAN DIEGO , Oct. 30, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it
Toggle Summary Zogenix Acquires U.K.-Based Brabant Pharma
Obtains global rights for treatment option in development for Dravet syndrome, a rare and catastrophic form of epilepsy that begins in infancy Plans to initiate Phase 3 clinical studies of Brabafen™ in second quarter of 2015 Conference call and webcast today, October 27 , at 4:30 pm ET SAN DIEGO,
Toggle Summary Zogenix Submits Modified Formulation of Zohydro(R) ER With Potential Abuse Deterrent Properties for FDA Review
SAN DIEGO , Oct. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it has submitted to the U.S.
Toggle Summary New Data Shows Zohydro(R) ER Reduced Pain and Improved Function in People With Chronic Pain
Moderate and Substantial Levels of Pain Relief Produce the Greatest Functional Benefits With Zohydro(R) ER (hydrocodone bitartrate) Extended-Release Capsules, CII PHOENIX , Sept. 18, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing
Toggle Summary Education, Patient-Focused Approach to Treating Chronic Pain Are Keys to Preventing Opioid Abuse, Say Experts, Patients
Patients Want Access to a Full Range of FDA-Approved Medications and Pain Relief That Lasts for the Duration of the Prescribed Dosing SAN DIEGO , Sept. 4, 2014 (GLOBE NEWSWIRE) -- When leading health care professionals, chronic pain patients and pain community advocates gathered recently to kick
Toggle Summary Zogenix to Participate in Morgan Stanley Global Healthcare Conference 2014
SAN DIEGO , Sept. 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Zogenix management will present at the Morgan Stanley
Toggle Summary Zohydro(R) ER Demonstrates Sustained 12-Hour Pain Relief
No Additional Nighttime Dosing and No End-of-Dose Failure, in Most Patients, According to Post-Hoc Analysis Presented at PAINWeek SAN DIEGO , Sept. 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of
Toggle Summary Zogenix Reports Second Quarter 2014 Financial Results
Conference Call and Webcast Today, August 5, at 4:30 p.m. ET Recent Business Highlights Provided updated timeline for abuse deterrent formulations of Zohydro ® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with sNDA for first candidate expected to be filed by October, with potential
Toggle Summary Zogenix Announces Departure of Chief Commercial Officer, Scott Shively
SAN DIEGO , Aug. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Scott Shively has resigned as Chief Commercial Officer
Toggle Summary Zogenix Announces Conference Call and Webcast to Present Second Quarter 2014 Financial Results
Conference Call Scheduled for August 5, 2014 at 4:30 pm ET SAN DIEGO , July 22, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it
Toggle Summary Zogenix Announces Appointment of David Brushwood, J.D., R.Ph., to External Safe Use Board
Board Commends Comprehensive Surveillance Program, Educational Efforts for Zohydro(R) ER SAN DIEGO , July 17, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous
Toggle Summary Zogenix Announces New Patent Valid Through 2032 For DosePro(R) Needle-Free Delivery System
Covers Fundamental Delivery Profile Needed to Achieve Reliable Subcutaneous Jet Injection SAN DIEGO , July 14, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) announced today the issuance of a new patent, US 8,734,384, from the United States Patent and Trademark Office (USPTO).
Toggle Summary Zogenix Reports Positive Development on U.S. District Court Ruling
Judge Upholds Prior Decision That State Regulations Cannot Usurp Federal Law SAN DIEGO , July 9, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today commented on the order issued by the U.S. District Court in Massachusetts upholding its prior decision that imposing regulations to restrict
Toggle Summary Zogenix Provides Update on Development of Abuse Deterrent Formulations of Zohydro(R) ER
Application for Next Generation of Zohydro(R) ER to be Filed by October 2014 SAN DIEGO , July 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced an update on its development programs focused on the introduction of abuse deterrent formulations of Zohydro ® ER (hydrocodone
Toggle Summary Zogenix to Present at Two Upcoming Conferences
SAN DIEGO , June 16, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that Ann Rhoads , Chief Financial Officer, will be presenting at
Toggle Summary Zogenix Reports Granting of Inducement Awards
SAN DIEGO , June 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported today that it has issued inducement awards to four new non-executive
Toggle Summary Zogenix Officers to Report Withholding of Shares
SAN DIEGO , June 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, announced today that certain of its executive officers will submit Form 4 filings
Toggle Summary Zogenix to Present at Jefferies 2014 Global Healthcare Conference
SAN DIEGO , May 30, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that Stephen Farr , Ph.D., President, and Ann Rhoads , Chief
Toggle Summary Zogenix Closes Sale of SUMAVEL(R) DosePro(R) Migraine Therapy to Endo International
SAN DIEGO , May 19, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, announced today the closing of its previously announced sale of its SUMAVEL ®
Toggle Summary Zogenix Reports First Quarter 2014 Financial Results
Conference Call and Webcast Today, May 8, at 4:30 p.m. ET Recent Business Highlights Commercial and medical affairs organization began educational efforts to prescribers and pharmacists for Zohydro™ ER (hydrocodone bitartrate) extended-release capsules the first week in March Continued efforts to
Toggle Summary Zogenix Reports Granting of Inducement Awards
SAN DIEGO , May 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported today that it has issued inducement awards to five new non-executive
Toggle Summary Zogenix Announces Conference Call and Webcast to Present First Quarter 2014 Financial Results
Conference Call Scheduled for May 8, 2014 at 4:30 pm ET SAN DIEGO , April 30, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it will
Toggle Summary Zogenix Announces Sale of SUMAVEL(R) DosePro(R) Migraine Therapy to Endo International
Conference Call Scheduled for 8:30 am ET on Thursday, April 24, 2014 SAN DIEGO , April 24, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, announced
Toggle Summary A Common Sense Approach to Appropriate Drug Use
SAN DIEGO , April 24, 2014 /PRNewswire/ -- We at Zogenix  have reviewed the letter to Vermont Governor Peter Shumlin signed by the Center for Lawful Access and Abuse Deterrence ( CLAAD ),  The American Academy of Pain Management and the National Fibromyalgia & Chronic Pain Association , which
Toggle Summary Zogenix Responds to Governor's Action Singling Out Zohydro™ ER in Massachusetts, Encourages Officials to Consider Patient Needs and Effective Class-Wide Measures
SAN DIEGO , April 23, 2014 /PRNewswire/ -- Zogenix will continue to work to ensure patients suffering from severe chronic pain have access to the FDA -approved medications they need in every state nationwide, including Massachusetts. We are once again disappointed that Governor Patrick would issue
Toggle Summary Zogenix Announces Ruling Preventing the Implementation of Massachusetts Governor's Order that Blocked Access to Zohydro™ ER
SAN DIEGO , April 15, 2014 /PRNewswire/ --  Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that the U.S. District Court in Massachusetts entered an order,
Toggle Summary Zogenix Update on Legal Action
SAN DIEGO , April 8, 2014 /PRNewswire/ -- Today Zogenix presented its case in U.S. District Court in Boston requesting an immediate order staying the ban on the U.S. Food and Drug Administration ( FDA )-approved prescription drug product, Zohydro™ ER (hydrocodone bitartrate) extended-release
Toggle Summary Zogenix Takes Legal Action in Federal Court to Block Massachusetts Improper Ban on Zohydro™ ER
Company Files for Injunction - Prescription Drug Status Should Reside Solely With the FDA SAN DIEGO , April 7, 2014 /PRNewswire/ --  Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS)
Toggle Summary FDA, HHS Reaffirm Support for Chronic Pain Patients Amid Zohydro ER Debate
SAN DIEGO , April 4, 2014 /PRNewswire/ -- Today, Health and Human Services (HHS) Secretary Kathleen Sebelius , and U.S. Food and Drug Administration ( FDA ) Commissioner Dr. Margaret Hamburg , called for a balanced approach in the fight against prescription drug abuse and preserving the protection
Toggle Summary Zogenix Statement: Let's Get the Facts Straight About Zohydro ER
SAN DIEGO , April 2, 2014 /PRNewswire/ -- We are extremely disappointed that the U.S. Drug Enforcement Administration (DEA) Administrator, as she did in a Congressional hearing today, would repeat misinformation about Zohydro™ ER that has been demonstrated to be false.
Toggle Summary Zogenix Reports Granting of Inducement Awards
SAN DIEGO , April 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported today that it has issued inducement awards to two new non-executive
Toggle Summary Zogenix Statement: Massachusetts Denies Patients a Legitimate Option for Severe Chronic Pain
SAN DIEGO , March 27, 2014 /PRNewswire/ -- We agree with Governor Deval Patrick's intention to curb the epidemic of drug abuse in Massachusetts . However, we are extremely concerned by his unprecedented action with respect to a specific FDA -approved prescription medication.
Toggle Summary Zogenix Appoints James Breitmeyer to Its Board of Directors
SAN DIEGO , March 26, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, announced today that James B.
Toggle Summary Dr. Marsha Stanton Receives 2014 American Academy of Pain Medicine Distinguished Service Award
SAN DIEGO , March 7, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that the American Academy of Pain Medicine (AAPM) has presented
Toggle Summary Zogenix Reports Fourth Quarter and Full Year 2013 Financial Results
Conference Call and Webcast Today, March 5, at 4:30 p.m. ET Business Highlights and Milestones Raised net proceeds of $64.5 million in a public offering of common stock Expanded medical and commercial leadership teams, and sales force to 150 representatives Completed preparations for responsible
Toggle Summary Zogenix Reports Granting of Inducement Awards
SAN DIEGO , March 5, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported today that it has issued inducement awards to 102 new non-executive
Toggle Summary Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2013 Financial Results
Conference Call Scheduled for March 5, 2014 at 4:30 pm ET SAN DIEGO , Feb. 27, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced it
Toggle Summary Zogenix Establishes External Safe-Use Board
Experts to Provide Independent Oversight and Recommendations SAN DIEGO , Feb. 12, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced the
Toggle Summary Zogenix Provides Update on Zohydro(TM) ER (hydrocodone bitartrate) Launch Readiness Plans
Zogenix in Final Preparations for Early March Market Launch SAN DIEGO , Feb. 11, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced
Toggle Summary Zogenix to Present at Leerink Swann 2014 Global Healthcare Conference
SAN DIEGO , Feb. 4, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, today announced that Stephen J. Farr , Ph.D., President, and Ann Rhoads , Chief Financial
Toggle Summary Zogenix Reports Granting of Inducement Awards
SAN DIEGO , Feb. 4, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, reported today that it has issued inducement awards to fourteen new non-executive employees.
Toggle Summary Zogenix Announces Preliminary Fourth Quarter 2013 Gross Product Sales
SAN DIEGO , Jan. 13, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced today preliminary unaudited gross product sales on sales of SUMAVEL ® DosePro ® for
Toggle Summary Zogenix and Mallinckrodt Agree to End Co-Promotion for SUMAVEL(R) DosePro(R) Effective January 31, 2014
SAN DIEGO , Jan. 9, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, and Mallinckrodt (NYSE:MNK) announced today that the co-promotion of SUMAVEL ® DosePro ®
Toggle Summary Zogenix Reports Granting of Inducement Awards
SAN DIEGO , Jan. 7, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, reported today that it has issued inducement awards to two new non-executive employees.
Toggle Summary Zogenix Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Dec. 20, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, reported today that it has issued an inducement award to Bradley S.
Toggle Summary Zogenix Appoints Chief Medical Officer and Expands Medical Leadership Team
Additional Clinical and Medical Affairs Leaders Join Zogenix to Support Zohydro(TM) ER Launch SAN DIEGO , Dec. 17, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain,
Toggle Summary Zogenix Reports Granting of Inducement Awards
SAN DIEGO , Dec. 11, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, reported today that it has issued inducement awards to twelve new non-executive employees.
Toggle Summary Zogenix Announces FDA Approval of 4 mg SUMAVEL(R) DosePro(R) (sumatriptan injection) Needle-Free Delivery System
SAN DIEGO , Dec. 10, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders and pain, announced today that the U.S. Food and Drug Administration ( FDA ) has approved the
Toggle Summary Zogenix to Present at the Oppenheimer 24th Annual Healthcare Conference
SAN DIEGO , Dec. 4, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, today announced that Ann Rhoads , Chief Financial Officer will present at the Oppenheimer 24 th
Toggle Summary Zogenix and Battelle Expand DosePro Technology Business Agreement
New Long-Term Agreement Reflects Significant Opportunities to Out-License DosePro Technology SAN DIEGO and COLUMBUS, Ohio , Dec. 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) and Battelle today announced that they have entered into a new long-term collaborative agreement regarding
Toggle Summary Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters
SAN DIEGO , Nov. 12, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced today the closing of its previously announced public offering of 30,666,667 shares of
Toggle Summary Zogenix Prices Public Offering of Common Stock
SAN DIEGO , Nov. 5, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced today that it has priced an underwritten public offering of 26,666,667 shares of its
Toggle Summary Zogenix Announces Proposed Public Offering of Common Stock
SAN DIEGO , Nov. 4, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced today that it intends to offer and sell $60 million of shares of its common stock in
Toggle Summary Zogenix Reports Third Quarter 2013 Financial Results
Business Highlights and Milestones Received FDA Approval for Zohydro™ ER (hydrocodone bitartrate), an extended-release oral formulation of hydrocodone without acetaminophen Announced development and option agreement with Altus Formulation Inc. for abuse deterrent formulations of Zohydro ER Began
Toggle Summary Zogenix Pursues Development of Abuse Deterrent Formulations of Zohydro(TM) ER With Altus Formulation
SAN DIEGO , Nov. 1, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, today announced that it has entered into a Development and Option Agreement ("D&O
Toggle Summary Zogenix Receives FDA Approval for Zohydro(TM) ER (hydrocodone bitartrate) Extended-Release Capsules
Conference Call and Webcast on Monday, October 28, at 8:30 a.m. ET SAN DIEGO , Oct. 25, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, today announced that the
Toggle Summary Zogenix Provides Update on Zohydro(TM) ER NDA
SAN DIEGO , Oct. 1, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced that it has been informed today by the U.S.
Toggle Summary Zogenix Reports Second Quarter 2013 Financial Results
Conference Call and Webcast Today, August 8 , at 4:30 p.m. ET SUMAVEL ® DosePro ® (sumatriptan injection) Second Quarter 2013 Highlights Net product revenue of $8.9 million , up 11% over the second quarter 2012 Generated approximately 20,000 total prescriptions Maintained positive quarterly refill
Toggle Summary Zogenix Announces Conference Call and Webcast to Present Second Quarter 2013 Financial Results
Conference Call Scheduled for August 8, 2013 at 4:30 pm ET SAN DIEGO , Aug. 5, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release
Toggle Summary Zogenix Begins Promotion of Migranal(R) Nasal Spray
Expands Portfolio of Differentiated Migraine Therapies SAN DIEGO , Aug. 1, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that its sales force has
Toggle Summary Zogenix and Valeant Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Migranal(R) Nasal Spray
Zogenix Sales Force to Begin Promoting Migranal(R) to Its Customer Base of Neurologists and Headache Specialists SAN DIEGO , June 27, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system
Toggle Summary Zogenix Launches Improved Migraine Toolbox in Conjunction With National Migraine Awareness Month
Supports Patient Education and Empowerment for Managing Multiple Types of Migraine Attacks SAN DIEGO , June 25, 2013 (GLOBE NEWSWIRE) -- In conjunction with National Migraine Awareness Month and in recognition of the significant unmet needs of migraine sufferers, Zogenix, Inc.
Toggle Summary Zogenix Announces Initiatives to Reach Key Business Milestones
Cost Control Initiatives Extend Cash Runway SAN DIEGO , June 5, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today initiatives to extend its cash
Toggle Summary Zogenix and Battelle to Present Positive, New Data Demonstrating Value of Needle-Free Injection for Biologics
DosePro Studies to be Presented at 2013 AAPS National Biotechnology Conference SAN DIEGO and COLUMBUS, Ohio, May 20, 2013 (GLOBE NEWSWIRE via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) and Battelle Memorial Institute today announced new data supporting the value of the DosePro® needle-free injection
Toggle Summary Zogenix Reports First Quarter 2013 Financial Results
Provides Update on Zohydro ER Conference Call and Webcast Today, May 9 , at 4:30 p.m. ET SUMAVEL ® DosePro ® (sumatriptan injection) First Quarter 2013 Highlights Net product revenue of $7.0 million , reflecting a $1.2 million net adjustment to future product return reserve Generated approximately
Toggle Summary Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET SAN DIEGO , May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial
Toggle Summary Zogenix Reports Positive Top-Line Results From Extended Relday(TM) Phase 1 Clinical Trial
Initiates Efforts to Secure Strategic Development and Commercialization Partner SAN DIEGO , May 2, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced
Toggle Summary Zogenix and Battelle Extend DosePro Co-Marketing Partnership
SAN DIEGO and COLUMBUS, Ohio, Mar 27, 2013 (GLOBE NEWSWIRE via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, and Battelle, the world's largest independent research and
Toggle Summary Zogenix Reports Fourth Quarter and Full Year 2012 Financial Results
Conference Call and Webcast Today, March 15, at 8:30 a.m. ET SUMAVEL ® DosePro ® (sumatriptan injection) Highlights 2012 net product revenue of $35.9 million , up 18% over 2011 Fourth quarter net product revenue of $9.5 million , up 12% over third quarter Increased total prescriptions to over
Toggle Summary Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2012 Financial Results
Conference Call Scheduled for March 15, 2013 at 8:30 am ET SAN DIEGO , March 7, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release
Toggle Summary Zogenix Provides Update on Zohydro(TM) ER Regulatory Review
SAN DIEGO , Feb. 26, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it has been informed by the U.S.
Toggle Summary Zogenix Announces Preliminary Fourth Quarter 2012 Gross Product Sales
SAN DIEGO , Jan. 7, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today preliminary unaudited gross product sales for the quarter ended December 31,
Toggle Summary Zogenix Reports Positive Results From Relday(TM) Phase 1 Clinical Trial
Plans to Seek Partner and Accelerate Development of Once-Monthly Subcutaneous Formulation of Risperidone for Schizophrenia SAN DIEGO , Jan. 3, 2013 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous
Toggle Summary Zogenix Provides Update on FDA Advisory Committee Meeting for Zohydro(TM) ER for Management of Chronic Pain
Zogenix to Host Conference Call on Dec. 7, 2012 at 6:30 p.m. ET SAN DIEGO , Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that the U.S.
Toggle Summary Trading of Zogenix Common Stock Halted
FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application Zogenix to Host Conference Call at 6:30 pm ET Today SAN DIEGO , Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous
Toggle Summary Zogenix Appoints New Chief Commercial Officer
SAN DIEGO, Nov. 26, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced the appointment of R. Scott Shively to serve as executive vice president and
Toggle Summary Zogenix to Present at the 24th Annual Piper Jaffray Healthcare Conference
SAN DIEGO , Nov. 15, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Roger L. Hawley , Chief Executive Officer, and Ann Rhoads , Executive Vice
Toggle Summary Preliminary Findings From Rheumatoid Arthritis Patient Survey Reveal Strong Interest in Needle-Free Self-Injection
Survey Finds RA Patients' Willingness to Accept Prescriptions for Self-Injected Medication Substantially Increases if Needle-Free Option Available COLUMBUS, Ohio and SAN DIEGO, Nov. 13, 2012 (GLOBE NEWSWIRE) -- Battelle, the world's largest independent research and development organization and
Toggle Summary Zogenix Reports Third Quarter 2012 Financial Results
Growth Continues in Product Sales and Pipeline Remains on Track Conference Call and Webcast Today, November 8th , at 4:30 p.m. ET SUMAVEL ® DosePro ® (sumatriptan injection) Third Quarter 2012 Highlights $8.5 million net product revenue, 5% increase over the second quarter 2012 Zogenix team
Toggle Summary Zogenix Announces FDA Advisory Committee Review of Zohydro(TM) ER for the Management of Chronic Pain
SAN DIEGO , Nov. 8, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that the U.S. Food and Drug Administration's ( FDA ) Anesthetic and Analgesic
Toggle Summary Zogenix Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
Conference Call Scheduled for November 8, 2012 at 4:30 pm ET SAN DIEGO , Oct. 25, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release
Toggle Summary Zogenix to Present New Case Study Highlighting Successful Repositioning of Injectable Sumatriptan for Migraine With a Novel Needle-Free Delivery Technology
Presentation at the 2nd Annual Drug Repositioning & Indications Discovery Conference to Demonstrate Increased Adoption of a Standard Therapy Used With DosePro(R) Technology SAN DIEGO , Oct. 23, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and
Toggle Summary Zogenix Announces Availability of New Resources for Migraine Sufferers at www.SUMAVELDosePro.com to Support National Pain Awareness Month
Features Attack-Specific Treatment Guidelines and Video Resources SAN DIEGO , Sept. 27, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today the
Toggle Summary Zogenix to Present at Stifel Nicolaus 2012 Healthcare Conference
SAN DIEGO , Aug. 30, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Roger L. Hawley , Chief Executive Officer, and Ann Rhoads , Executive Vice
Toggle Summary Zogenix Reports Second Quarter 2012 Financial Results
Reiterates 2012 Financial Guidance Conference Call and Webcast Today, August 8th , at 4:30 p.m. ET SUMAVEL ® DosePro ® (sumatriptan injection) Second Quarter 2012 Highlights Successfully retained prescribers called on by the Zogenix sales force, increasing their total prescriptions by 6% over the
Toggle Summary Zogenix Repays Outstanding Loan With Oxford Finance LLC and Silicon Valley Bank
Eliminates Monthly Principal and Interest Payments SAN DIEGO , Aug. 1, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it has repaid all
Toggle Summary Zogenix Announces Conference Call and Webcast to Present Second Quarter 2012 Financial Results
Conference Call Scheduled for August 8, 2012 at 4:30 pm ET SAN DIEGO , July 31, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release
Toggle Summary Zogenix and Battelle Launch "Less is More" DosePro(R) Marketing Campaign
Campaign Targets Biopharmaceutical and Government Potential Out-Licensing Opportunities SAN DIEGO and COLUMBUS, Ohio , July 30, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system
Toggle Summary Zogenix Prices Public Offering of Common Stock and Warrants to Purchase Common Stock
SAN DIEGO , July 24, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that it has priced an underwritten public offering of 32,500,000 units.
Toggle Summary Zogenix Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
SAN DIEGO , July 23, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that it intends to offer units in an underwritten public offering, with each
Toggle Summary Zogenix Announces U.S. Food and Drug Administration (FDA) Acceptance for Review of Zohydro ER(TM) New Drug Application (NDA) for Treatment of Chronic Pain
SAN DIEGO , July 16, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that the U.S. Food and Drug Administration ( FDA ) has accepted for review the
Toggle Summary Zogenix Begins Relday(TM) Clinical Trial for Schizophrenia
Patient Screening and Enrollment Underway With Results Anticipated Before Year-End First-in-Class Needle-Free Once-Monthly Formulation Using DosePro® Delivery System SAN DIEGO , July 12, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing
Toggle Summary Zogenix and Mallinckrodt, a Covidien Company, Enter Exclusive Co-Promotion Agreement for SUMAVEL(R) DosePro(R)
Mallinckrodt Pain Management Sales Force to Begin Promoting SUMAVEL DosePro to Primary Care Customers August 2012 SAN DIEGO , June 7, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system
Toggle Summary Zogenix Submits IND for Second DosePro(R) Candidate Relday(TM)
Potential First Needle-Free Subcutaneous Treatment Option in $2 Billion Long-Acting Injectable Antipsychotic Market SAN DIEGO , May 30, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system
Toggle Summary Zogenix Reports First Quarter 2012 Financial Results
Reiterates 2012 Financial Guidance Conference Call and Webcast Today, May 14th, at 4:30 p.m. ET SUMAVEL(R) DosePro(R) (sumatriptan injection) Highlights -- Total revenues of $18.3 million achieved in the first quarter 2012 -- Net product revenue increased to $9.9 million in the first quarter 2012,
Toggle Summary Zogenix Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
Conference Call Scheduled for May 14, 2012 at 4:30 pm ET SAN DIEGO , May 3, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release
Toggle Summary Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro(TM) for Treatment of Chronic Pain
First NDA Submission for an Extended-Release Hydrocodone Therapy without Acetaminophen SAN DIEGO, May 2, 2012 /PRNewswire via COMTEX/ --Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain,
Toggle Summary Zogenix and Battelle Ink Marketing Agreement for DosePro(R) Drug Delivery Technology
Collaboration Opens Possibilities for New DosePro Applications That Offer Validated Needle-Free Subcutaneous Drug Delivery to Bio-Pharma Community SAN DIEGO and COLUMBUS, Ohio, March 29, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX ), a pharmaceutical company commercializing and developing
Toggle Summary Zogenix Reports Fourth Quarter and Full Year 2011 Financial Results
Conference Call and Webcast Today, March 8th, at 4:30 p.m. ET SUMAVEL ® DosePro ® (sumatriptan injection) Highlights Increased total prescriptions to over 71,000 in 2011, a 104% increase over 2010* Increased total prescriptions to over 21,000 in the fourth quarter 2011, 13% higher than the third
Toggle Summary Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2011 Financial Results
Conference Call Scheduled for March 8, 2012 at 4:30 pm ET SAN DIEGO , Feb. 27, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release
Toggle Summary Zogenix to Present at Leerink Swann 2012 Global Healthcare Conference
SAN DIEGO , Feb. 10, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Stephen J. Farr , Ph.D., President and Chief Operating Officer, and Ann
Toggle Summary Zogenix and Battelle to Collaborate on Advanced Drug Delivery Technology
Includes Option for Joint Development of Expanded DosePro(R) Drug Delivery Platform SAN DIEGO and COLUMBUS, Ohio , Jan. 25, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders
Toggle Summary Zogenix Reviews Positive Sales Trends and 2012 Commercial Initiatives for SUMAVEL(R) DosePro(R)
Evaluating New Co-Promotion Opportunities to Supplement Zogenix U.S. Sales Team Zogenix to Host Conference Call Today at 9:00 am ET SAN DIEGO , Dec. 21, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of
Toggle Summary Zogenix and Astellas Agree to End Co-Promotion for SUMAVEL(R) DosePro(R) Effective March 31, 2012
SAN DIEGO and Deerfield, Ill. , Dec. 21, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, and Astellas Pharma US, Inc. (Astellas), a U.S.
Toggle Summary Zogenix Completes Zohydro(TM) Pre-NDA Meetings With FDA
Zohydro NDA Submission on Track SAN DIEGO , Dec. 20, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it has concluded its pre-New Drug
Toggle Summary Zogenix to Present at Two Upcoming Conferences
SAN DIEGO, Nov 21, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Roger L. Hawley, Chief Executive Officer, and Ann Rhoads,
Toggle Summary Zogenix Reports Third Quarter 2011 Financial Results
Zogenix Continued Growth of SUMAVEL DosePro Prescriptions and Reported Positive Phase 3 Efficacy Results on Zohydro Conference Call and Webcast Today, November 10th, at 4:30 p.m. ET SUMAVEL(R) DosePro(R) (sumatriptan injection) Highlights -- Increased total prescriptions by 6% sequentially from
Toggle Summary Zogenix Announces Conference Call and Webcast to Present Third Quarter 2011 Financial Results
Conference Call Scheduled for November 10, 2011 at 4:30 pm ET SAN DIEGO, Nov 4, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will
Toggle Summary Zogenix to Host Investor Meeting on October 13, 2011
SAN DIEGO, Oct 12, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that it will host an investor meeting on Thursday, October 13, 2011,
Toggle Summary Zogenix Achieves Zohydro(TM) Long-Term Safety Database for NDA
NDA Submission Remains on Track for Early 2012 SAN DIEGO, Sep 30, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it has obtained the
Toggle Summary Zogenix to Present at UBS 2011 Global Life Sciences Conference
SAN DIEGO, Sep 19, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Stephen J. Farr, Ph.D., President and Chief Operating Officer, and
Toggle Summary Zogenix Prices Public Offering of Common Stock
SAN DIEGO, Sep 16, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) announced today the pricing of its underwritten public offering of 30,000,000 shares of its common stock at $2.00 per share, before underwriting discounts and commissions.
Toggle Summary Zogenix Files Registration Statement for Proposed Follow-On Offering
SAN DIEGO, Aug 24, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 12,000,000 shares of its common
Toggle Summary Zogenix Reports Positive Phase 3 Results for Zohydro -- Meets Primary Efficacy Endpoint
First Extended-Release Hydrocodone Product Without Acetaminophen NDA Submission Expected by Early 2012 Conference Call and Webcast Today, August 17th, at 8:30 a.m. ET SAN DIEGO, Aug. 17, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing
Toggle Summary Zogenix to Hold Conference Call to Discuss Pivotal Phase 3 Results for Zohydro for Treatment of Chronic Pain
Conference Call and Webcast Scheduled for 8:30 a.m. ET on August 17, 2011 SAN DIEGO, Aug 16, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today
Toggle Summary Zogenix Reports Second Quarter 2011 Financial Results
Zohydro Pivotal Phase 3 Results Expected By End of August Conference Call and Web Cast Today, August 10th, at 4:30 p.m. ET SUMAVEL(R) DosePro(R) Highlights -- Achieved second quarter 2011 U.S. net product revenue of $8.7 million, representing 16% growth over the first quarter -- Zogenix sales force
Toggle Summary Zogenix Announces Publication of SUMAVEL(R) DosePro(R) Phase 4 Clinical Data
SAN DIEGO, Aug 4, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today the publication of its SUMAVEL DosePro (sumatriptan injection)
Toggle Summary Zogenix Announces 2011 Second Quarter Conference Call and Webcast
Earnings Call Scheduled for August 10, 2011 at 4:30 p.m. ET SAN DIEGO, Aug 2, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced it will release financial results for the second quarter ended June 30, 2011, after the market closes on Wednesday, August 10, 2011, and will
Toggle Summary Zogenix Closes $30 Million Royalty Financing With Cowen Healthcare Royalty Partners II
Includes $1.5 Million Equity Investment SAN DIEGO, Jul 18, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that it closed its previously
Toggle Summary Zogenix to Develop and Commercialize Proprietary Long-Acting Risperidone Formulation for Needle-Free Subcutaneous Administration Using the DosePro(R) Delivery System and DURECT's SABER(TM) Depot Technology
  Potential to Address $16 Billion World-Wide Antipsychotics Market SAN DIEGO and CUPERTINO, Calif., July 12, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX - News ), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders
Toggle Summary Zogenix Enters $30 Million Royalty Financing Agreement With Cowen Healthcare Royalty Partners II
Includes an Additional $1.5 Million Equity Investment SAN DIEGO, Jun 30, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that it has
Toggle Summary Zogenix to Present at 2011 Wells Fargo Securities Healthcare Conference
SAN DIEGO, Jun 13, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Chief Executive Officer Roger L.
Toggle Summary Fast-Acting Migraine Treatment Highlighted During National Migraine Awareness Month
SUMAVEL® DosePro® Provides Treatment Option for Migraine Patients; Addresses 50% of Oral Triptan Users who are Dissatisfied with their Current Migraine Therapy SAN DIEGO, June 6, 2011 /PRNewswire via COMTEX/ -- Thirty-six million Americans suffer from migraines , leading to more than $20 billion in
Toggle Summary Zogenix to Present Additional SUMAVEL(R) DosePro(R) Phase 4 Results at Headache Meetings in June
New Data Analyzes Efficacy, Tolerability, and Patient Preference for SUMAVEL DosePro Among Current Triptan Users Requiring a Change in Migraine Therapy SAN DIEGO, May 27, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that additional data from the Company's Phase 4
Toggle Summary Zogenix Stockholders Elect Mark Wiggins to Board of Directors
SAN DIEGO, May 25, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that the Company's stockholders have elected Mark Wiggins as a new
Toggle Summary Zogenix Highlights DosePro(R) Needle-Free Delivery System at 2011 AAPS National Biotechnology Conference
SAN DIEGO, May 18, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that it presented three posters highlighting its proprietary DosePro(R) Needle-free Delivery System (DosePro) at the 2011 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology
Toggle Summary Zogenix Reports First Quarter 2011 Financial Results
Confirms 2011 Financial Guidance Conference Call and Web cast Today, May 16th, at 4:30 p.m. ET SUMAVEL(R) DosePro(R) U.S. Highlights -- First quarter 2011 U.S. net product revenue of $7.5 million, up 10% over the fourth quarter 2010 -- Presented positive Phase 4 results at American Academy of
Toggle Summary Zogenix to Highlight DosePro(R) Needle-Free Delivery System at 2011 AAPS National Biotechnology Conference
SAN DIEGO, Calif., May 11, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that it will present three posters highlighting its proprietary DosePro(R) Needle-free Delivery System at the 2011 American Association of Pharmaceutical Scientists (AAPS) National
Toggle Summary Zogenix to Hold Conference Call to Discuss First Quarter 2011 Financial Results
Conference Call and Webcast Scheduled on May 16, 2011 at 4:30pm ET SAN DIEGO, May 4, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced it will release financial results for the first quarter ended March 31, 2011 after market close on Monday, May 16, 2011 at 4:00 p.m.
Toggle Summary Zogenix Demonstrates Increased Overall Patient Satisfaction With SUMAVEL(R) DosePro(R) Over Multiple Migraine Attacks
Phase 4 Clinical Data Presented at AAN Annual Meeting SAN DIEGO, Apr 13, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today reported clinical data from its Phase 4 open-label, multicenter study of SUMAVEL(R) DosePro (R) (sumatriptan injection) Needle-free Delivery System.
Toggle Summary Zogenix Announces SUMAVEL(R) DosePro(R) Named Patient Program
SAN DIEGO, Apr 12, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced the establishment of a Named Patient Program for SUMAVEL(R) DosePro(R) (sumatriptan injection) Needle-free Delivery System. A Named Patient Program is a mechanism through which physicians can legally
Toggle Summary Zogenix Announces Extension of SUMAVEL(R) DosePro(TM) U.S. Patent Protection by Eight Years
Newly Issued Patent Covers Product Until 2025 SAN DIEGO, Mar 16, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today confirmed that a recently issued
Toggle Summary Zogenix Reports Fourth Quarter and Full Year 2010 Financial Results
Provides 2011 Top-line Guidance Conference Call and Webcast Today, March 3rd, at 4:30 p.m. EST SUMAVEL(R) DosePro(TM) 2010 Adoption Highlights -- Fourth quarter 2010 net product revenue up 27% over third quarter 2010 -- More than 35,200 SUMAVEL DosePro prescriptions were filled from launch through
Toggle Summary Zogenix to Present SUMAVEL(R) DosePro(TM) Phase 4 Results at American Academy of Neurology
New Data on Treatment Satisfaction, Efficacy and Tolerability Across Multiple Migraine Attacks SAN DIEGO, Mar 1, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that data from a Phase 4 clinical study of SUMAVEL(R) DosePro(TM) (sumatriptan injection) Needle-free
Toggle Summary Zogenix to Hold Conference Call to Discuss Fourth Quarter and Full Year 2010 Financial Results
Conference Call and Webcast Scheduled on March 3, 2011 at 4:30pm ET SAN DIEGO, Feb 16, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced it will release financial results for the fourth quarter and full year ended December 31, 2010 after market close on Thursday, March
Toggle Summary Zogenix Announces Completion of Enrollment in ZX002 Phase 3 Efficacy Study
Potential to be First Single-Entity, Controlled Release Hydrocodone Product SAN DIEGO, Feb 10, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) announced today the completion of enrollment in its pivotal Phase 3 efficacy study (Study 801) of ZX002.
Toggle Summary Zogenix Receives 2011 Drug Delivery Partnerships Innovation Award for SUMAVEL(R) DosePro(TM)
SAN DIEGO, Feb 9, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) today announced that it has received the 2011 Drug Delivery Partnerships(TM) ("DDP") Innovation Award in the Industry Achievement category for SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery
Toggle Summary Zogenix to Participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
SAN DIEGO, Feb 8, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that Chief Executive Officer Roger L. Hawley, along with Executive Vice President and Chief Financial Officer Ann Rhoads, will participate in the Leerink Swann Hot Topics in Therapeutics Roundtable
Toggle Summary Zogenix and Desitin Announce Marketing Approval for SUMAVEL(R) DosePro(TM) in Germany and the United Kingdom
SAN DIEGO and HAMBURG, Germany, Jan 6, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) and Desitin Pharmaceuticals GmbH ("Desitin") today announced that the Federal Institute for Drugs and Medical Devices of Germany (BrArM), and the Medicines and Healthcare products
Toggle Summary Zogenix Announces Partial Exercise of Over-Allotment Option for Initial Public Offering
SAN DIEGO, Dec 23, 2010 (GlobeNewswire via COMTEX) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) announced today that the underwriters of its recently completed initial public offering of common stock have partially exercised their option to purchase shares of common stock from Zogenix to cover
Toggle Summary Zogenix Receives 2010 Most Innovative Product Award for SUMAVEL(R) DosePro(TM)
SAN DIEGO, Dec 13, 2010 (GlobeNewswire via COMTEX) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) today announced that CONNECT, a regional San Diego nonprofit organization, selected SUMAVEL(R) DosePro(TM) (sumatriptan injection) Needle-free Delivery System as a 2010 Most Innovative Product (MIP) winner
Toggle Summary Zogenix and Desitin Announce First European Marketing Approval for SUMAVEL(R) DosePro(TM)
SAN DIEGO and HAMBURG, Germany, Dec 2, 2010 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) and Desitin Pharmaceuticals GmbH today announced that the Danish Medicines Agency of Denmark has approved the Marketing Authorization Application (MAA) for SUMAVEL(R) DosePro(TM) (sumatriptan
Toggle Summary Zogenix Announces Completion of Enrollment in ZX002 Phase 3 12-Month Safety Study
SAN DIEGO, Nov 30, 2010 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced completion of enrollment in its open-label Phase 3 safety study (Study 802) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate
Toggle Summary Zogenix Announces Pricing of Initial Public Offering
SAN DIEGO, Nov 22, 2010 (GlobeNewswire via COMTEX) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) announced today the pricing of its initial public offering of 14,000,000 shares of its common stock at $4.00 per share, before underwriting discounts and commissions.
Toggle Summary Zogenix Files Registration Statement for Proposed Initial Public Offering
SAN DIEGO, Calif., September 7, 2010 — Zogenix, Inc. (“Zogenix”) announced today that it has filed a registration statement with the Securities and Exchange Commission (”SEC”) relating to the proposed initial public offering of shares of its common stock.
Toggle Summary Zogenix Secures $35 Million Debt Facility And Raises $15 Million Investment Capital
SAN DIEGO, Calif., July 13, 2010 — Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, announced that it has secured a $35 million debt facility led by Oxford Finance Corporation which also included Silicon Valley Bank. The facility consists of a $25 million term loan and a $10
Toggle Summary Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone
SAN DIEGO, Calif., March 17, 2010 — Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen.
Toggle Summary ZOGENIX APPOINTS NEW CHIEF FINANCIAL OFFICER
SAN DIEGO, Calif., March 1, 2010 — Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, announced the appointment of Ann D. Rhoads to serve as the company’s chief financial officer (CFO). In addition to overseeing the day-to-day financial operations, Ms.
Toggle Summary SUMAVEL™ DosePro™ Available in the United States to Treat Acute Migraine and Cluster Headaches
− Innovative Needle-Free Delivery System Provides Fast Migraine Relief − SAN DIEGO, Calif. and DEERFIELD, Ill., January 13, 2010 Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, and Astellas Pharma U.S., Inc. (“Astellas”) announced today the U.S.
Toggle Summary Zogenix Increases Series B Preferred Stock Financing to $71 Million, Raising $35 Million in Second Tranche
- Dr. Arda M. Minocherhomjee of Chicago Growth Partners Joins Zogenix Board of Directors - SAN DIEGO, Calif., (December 7, 2009): Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, announced today that it has closed a $35 million second tranche of a Series B preferred stock
Toggle Summary Zogenix and Desitin Filing for European Regulatory Approval of SUMAVEL DosePro
- European Pivotal Trial Confirms Bioequivalence - SAN DIEGO, CA and Hamburg, Germany - (October 28, 2009): Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, and Desitin Pharmaceuticals GmbH (“Desitin”), a privately held, mid-sized German pharmaceutical company, today announced
Toggle Summary Zogenix and Astellas Announce Data Published Showing the Benefits of SUMAVEL DosePro Needle-Free Delivery System
- Data Published in Headache Highlights Bioequivalence, Safety and Ease of Use - SAN DIEGO, CA and DEERFIELD, IL - (October 22, 2009): Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, and Astellas Pharma US, Inc. (“Astellas”) announced that positive results from two clinical
Toggle Summary Zogenix Closes $51 million in Series B Preferred Stock Financing and Prepares for January 2010 Launch Of SUMAVEL™ DosePro™
SAN DIEGO, Calif., (September 23, 2009): Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, announced today that it has completed a $51 million Series B preferred stock financing. Clarus Ventures and Domain Associates, current investors in Zogenix, co-led the round with
Toggle Summary Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel DosePro
— Novel Product Recently Approved by the FDA for Treatment of Acute Migraine and Cluster Headache — SAN DIEGO, CA, and DEERFIELD, IL (August 3, 2009): Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company and Astellas Pharma US, Inc.
Toggle Summary Sumavel™ DosePro™ (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache
First Product Featuring Novel DosePro Needle-Free Delivery System SAN DIEGO, Calif., (July 16, 2009): Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA)
Toggle Summary Zogenix Reports FDA Provides New PDUFA Date for Sumavel™ DosePro™
- Potential Final Approval July 2009 - SAN DIEGO, Calif. – (February 18, 2009): Zogenix, Inc. (“Zogenix”), a private, specialty pharmaceutical company, announced that the U.S. Food & Drug Administration (FDA) has provided a target date of July 15, 2009 for completion of its review of the NDA
Toggle Summary Zogenix Closes $18 Million Financing with Oxford Finance Corporation and CIT Healthcare LLC
SAN DIEGO, Calif. - (July 25, 2008): Zogenix, Inc. (”Zogenix”), a privately held, specialty pharmaceutical company, announced today it has closed an $18 million secured loan facility with Oxford Finance Corporation and CIT Healthcare LLC. Zogenix will use the financing proceeds to continue to
Toggle Summary Zogenix Announces Clinical Study Results for sumatriptan DosePro™, a Novel Migraine Treatment
SAN DIEGO, Calif. - (June 28, 2008): Zogenix, Inc. (”Zogenix”), a private, specialty pharmaceutical company, today announced that it presented successful results from two clinical studies of sumatriptan DosePro, a product in development for treatment of acute migraine and cluster headache, at the
Toggle Summary Zogenix Completes Management Team with Cynthia Robinson, Ph.D., CDO, & Mark Thompson, VP, Sales & Managed Markets
SAN DIEGO, Calif. - (April 17, 2008): Zogenix, Inc. (”Zogenix”), a private, specialty pharmaceutical company, today announced that Cynthia “Candy” Robinson has joined the company as Chief Development Officer (CDO), and Mark Thompson has joined as Vice President, Sales and Managed Markets.
Toggle Summary Zogenix, Inc. Files Registration Statement for Proposed Initial Public Offering
SAN DIEGO, Calif. - (March 24, 2008): Zogenix, Inc. (”Zogenix”), a private, specialty pharmaceutical company, today announced that it has filed a registration statement with the Securities and Exchange Commission (”SEC”) relating to the proposed initial public offering of shares of its common
Toggle Summary Zogenix Announces sumatriptan DosePro™ NDA Accepted for Filing by FDA
SAN DIEGO, Calif. - (March 19, 2008): Zogenix, Inc. (”Zogenix”), a private, specialty pharmaceutical company, today announced that its New Drug Application (NDA) for sumatriptan DosePro™ has been accepted for filing by the U.S. Food and Drug Administration (FDA).
Toggle Summary Zogenix Licenses European Development and Commercial Rights for sumatriptan DosePro™ to Desitin Pharmaceuticals, GmbH
SAN DIEGO, CA (March 17, 2008) : Zogenix, Inc. (”Zogenix”), a private, specialty pharmaceutical company, today announced that it has entered into a license agreement to grant exclusive rights in the European Union to Desitin Pharmaceuticals, GmbH (”Desitin”) to develop and commercialize Zogenix’s
Toggle Summary Zogenix Raises $18 Million in Preferred Stock Financing
SAN DIEGO, CA (January 9, 2008) - Zogenix, Inc. (Zogenix), a private, specialty pharmaceutical company, today announced that the company has raised $18 million in a private placement of preferred stock. The financing was led by Abingworth Management Ltd.
Toggle Summary Zogenix Licenses Exclusive U.S. Commercial Rights for Late Stage, Controlled-Release, Opioid Product from Elan
SAN DIEGO, CA (November 27, 2007) Zogenix, Inc. (”Zogenix”), a private, specialty pharmaceutical company, today announced they have entered into a License Agreement under which Zogenix has been granted exclusive US rights from an affiliate of Elan Corporation, plc (NYSE: ELN) (”Elan”) to develop
Toggle Summary Zogenix Appoints David Nassif Executive Vice President and Chief Financial Officer
SAN DIEGO, CA (June 7, 2007) Zogenix, Inc., a privately held CNS-focused specialty pharmaceutical company, announced today that David Nassif has been appointed Executive Vice President and Chief Financial Officer. Mr. Nassif brings a breadth of life science experience across multiple roles,
Toggle Summary Zogenix Closes $10 Million Deal with GE Healthcare Financial Services
SAN DIEGO, CA (March 19, 2007) Zogenix, Inc., a privately held neuroscience-focused specialty pharmaceutical company, announced today it has received $3.5 million of a $10 million loan facility with GE Healthcare Financial Services. Zogenix will use the loan to finance the launch of its first